RCUS analyst estimates

Arcus Biosciences (RCUS) analyst ratings, the average price target and its range, and every firm's latest call.

RCUS analyst ratings and price targets

DateFirmCallTarget
Oct 21, 2026Truist FinancialArcus Biosciences price target raised to $41 from $40 at Truist$41.00
Sep 8, 2026Truist FinancialArcus Biosciences price target raised to $40 from $35 at Truist$40.00
Aug 10, 2026Morgan StanleyArcus Biosciences price target raised to $23 from $22 at Morgan Stanley$23.00
Aug 7, 2026Goldman SachsArcus Biosciences price target raised to $42 from $34 at Goldman Sachs$42.00
Aug 6, 2026WedbushArcus Biosciences price target raised to $43 from $41 at Wedbush$43.00
Jul 20, 2026H.C. WainwrightArcus Biosciences (RCUS) PT Raised to $45 at H.C. Wainwright$45.00
May 18, 2026Truist FinancialArcus Biosciences assumed with a Buy at Truist$35.00
May 11, 2026Morgan StanleyArcus Biosciences price target raised to $22 from $20 at Morgan Stanley$22.00
Apr 20, 2026Leerink PartnersArcus Biosciences price target lowered to $47 from $49 at Leerink$47.00
Feb 12, 2026Wells FargoArcus Biosciences downgraded to Equal Weight from Overweight at Wells Fargo$23.00
Jan 12, 2026Goldman SachsArcus Biosciences upgraded to Buy from Neutral at Goldman Sachs$28.00
Jan 8, 2026Morgan StanleyArcus Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley$20.00
Dec 12, 2025H.C. WainwrightArcus Biosciences price target raised to $32 from $28 at H.C. Wainwright$32.00
Dec 12, 2025Truist FinancialArcus Biosciences price target lowered to $30 from $39 at Truist$30.00
Oct 30, 2025Goldman SachsArcus Biosciences price target raised to $16 from $14 at Goldman Sachs$16.00

Updated 2026-11-03 11:31 UTC